CSIMarket Company Name, Ticker, Competitors, else..
 
Dynavax Technologies Corporation  (DVAX)
Other Ticker:  
 
 
Price: $11.1700 $0.20 1.823%
Day's High: $11.285 Week Perf: 2.76 %
Day's Low: $ 10.94 30 Day Perf: -0.89 %
Volume (M): 2,259 52 Wk High: $ 15.15
Volume (M$): $ 25,233 52 Wk Avg: $12.51
Open: $10.94 52 Wk Low: $9.74



 Market Capitalization (Millions $) 1,722
 Shares Outstanding (Millions) 154
 Employees 235
 Revenues (TTM) (Millions $) 360
 Net Income (TTM) (Millions $) 61
 Cash Flow (TTM) (Millions $) -44
 Capital Exp. (TTM) (Millions $) 4

Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company that develops and commercializes novel vaccines and therapeutics to prevent infectious diseases, cancer, and chronic inflammatory diseases. The company is headquartered in Emeryville, California, and was founded in 199

Dynavax's proprietary technology platforms include the Toll-like Receptor (TLR) and the C-Class CpG deoxyribonucleic acid (CpG DNA) technologies. These platforms stimulate the innate immune system and enhance the body's immune response to various pathogens and tumor antigens.

The company's lead product candidate is HEPLISAV-B, which is an adult hepatitis B vaccine designed to provide faster and more effective protection against hepatitis B compared to traditional vaccines. HEPLISAV-B was approved by the US Food and Drug Administration (FDA) in November 201

Dynavax is also developing SD-101, an investigational TLR9 agonist in phase 3 clinical trials for the treatment of advanced melanoma in combination with Keytruda. The company is also developing DV281, an investigational TLR7/8 agonist in phase 1 clinical trials for the treatment of non-small cell lung cancer.

In addition, Dynavax has partnerships and collaborations with several leading pharmaceutical companies and organizations, including AstraZeneca, GlaxoSmithKline, and the Bill & Melinda Gates Foundation.

Dynavax has a strong financial position, with a market capitalization of approximately $5 billion as of September 202 The company's total revenue for the second quarter of 2021 was $28.1 million, compared to $0 million for the same period in 2020. The company's net loss for the second quarter of 2021 was $68.7 million, compared to $31 million for the same period in 2020.

Overall, Dynavax Technologies Corp is a leading biopharmaceutical company with a promising pipeline of innovative vaccines and therapeutics for the prevention and treatment of infectious and chronic diseases. The company's unique technology platforms and strategic partnerships position it well for continued success in the biopharmaceutical industry.


   Company Address: 2100 Powell Street Emeryville 94608 CA
   Company Phone Number: 848-5100   Stock Exchange / Ticker: NASDAQ DVAX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Dynavax Technologies Corporation

Dynavax Technologies Corporation Struggles Amidst Steep Revenue Decline, but Surprises with Impressive Earnings Turnaround

Dynavax Technologies Corporation faced a challenging fiscal period from July to September 2023, as their earnings per share took a sharp dive of -76.74% to $0.10 compared to the previous year's $0.43. However, despite this significant decline, the company managed to double its earnings per share by an impressive 233.33% from the preceding quarter's $0.03.
The revenue of Dynavax Technologies Corporation also experienced a negative impact, plummeting by -59.153% to $68.51 million from $167.74 million in the same quarter of the previous year. However, there was a sequential increase of 13.718% from $60.25 million, which indicates some progress in the company's financial performance. It is important to note that this decline in revenue is an exception rather than the rule within the Major Pharmaceutical Preparations sector, which recorded revenue growth in the third quarter of 2023.
In line with the decrease in revenue, the net earnings of Dynavax Technologies Corporation for the July to September 2023 fiscal period fell by -77.6% to $14.293 million, compared to $63.809 million in the corresponding period a year before. These figures do reflect a considerable setback, but it's crucial to look holistically at the company's profitability during this period. The operating margin mitigated to 7.47%, and net margin shrank to 20.86%.
Dynavax Technologies Corporation

DVAX Stunned as Q2 2023 Profits Plummet, Sees An Alarmingly Huge 96.55% Drop in Income!



Dynavax Technologies Corporation (DVAX), a major player in the pharmaceutical industry, experienced a challenging second quarter in 2023, with plummeting income and a significant drop in revenue. These figures are in sharp contrast to the overall growth witnessed in the Major Pharmaceutical Preparations sector during the same period. This article will examine these financial results in detail and provide insight into the current state of Dynavax Technologies Corporation.
Income and Revenue Plunge:
In the second quarter of 2023, Dynavax Technologies Corporation reported a staggering 96.55% decrease in income compared to the previous year. This decline marks a significant downturn to just $0.03 per share, compared to $0.87 per share during the same period in 2022. However, it is worth noting that there was a positive turnaround from the preceding quarter's loss of $-0.19 per share.
Dynavax Technologies Corporation

Breaking down first quarter of 2023 effort, the company's saw very demanding period

Investors beware, as Dynavax Technologies Corporation has experienced a significant decline in its financial performance in the most recent fiscal period. With a negative earnings per share of $-0.19 compared to $0.22 a year before, it's clear that the company is struggling to maintain profitability.
Furthermore, income per share has fallen from $0.36 in the preceding reporting period, indicating a concerning trend of decreasing profitability for Dynavax Technologies Corporation. The revenue has also taken a massive hit, with a decline of 58.835% to $46.93 million from $113.99 million in the corresponding reporting period a year before. Sequentially, the revenue tumbled by an even more alarming 74.565% from $184.49 million.






Dynavax Technologies's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com